Phosphagenics and Nestle Nutrition Enters Research Agreement

Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Food and Agriculture on April 30, 2006

Phosphagenics Limited has given Nestle Nutrition the license to use Phospha E® for use in its nutritional products, in exchange for funding towards a full dose-response preclinical study of Phospha E® prior to full scale evaluation of the product in humans.

Phospa E is patented vitamin E phosphate, said to protect the antioxidant potential of vitamin E during absorption, transport and storage in the body. It is currently only marketed in the US, Canada and Indonesia by Zila Nutraceuticals, which markets it as Ester-E.

Nestle Nutrition may use Phospha E to develop nutritional products that target the prevention and treatment of metabolic syndrome, a group of risk factors for heart disease, including excessive weight, high blood pressure, high blood sugar and triglyceride concentrations, and other factors contributing to cardiovascular disease.

See Nutraingredients.com for a feature report. Other public details of the agreement may be found here.